JP2018534245A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534245A5
JP2018534245A5 JP2018513462A JP2018513462A JP2018534245A5 JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5 JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5
Authority
JP
Japan
Prior art keywords
domain
family
igsf
modified
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051786 external-priority patent/WO2017048878A1/en
Publication of JP2018534245A publication Critical patent/JP2018534245A/ja
Publication of JP2018534245A5 publication Critical patent/JP2018534245A5/ja
Pending legal-status Critical Current

Links

JP2018513462A 2015-09-14 2016-09-14 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法 Pending JP2018534245A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562218531P 2015-09-14 2015-09-14
US62/218,531 2015-09-14
US201662323595P 2016-04-15 2016-04-15
US201662323608P 2016-04-15 2016-04-15
US62/323,595 2016-04-15
US62/323,608 2016-04-15
US201662367819P 2016-07-28 2016-07-28
US201662367822P 2016-07-28 2016-07-28
US62/367,819 2016-07-28
US62/367,822 2016-07-28
PCT/US2016/051786 WO2017048878A1 (en) 2015-09-14 2016-09-14 Tunable variant immunoglobulin superfamily domains and engineered cell therapy

Publications (2)

Publication Number Publication Date
JP2018534245A JP2018534245A (ja) 2018-11-22
JP2018534245A5 true JP2018534245A5 (enExample) 2019-10-24

Family

ID=57068203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513462A Pending JP2018534245A (ja) 2015-09-14 2016-09-14 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法

Country Status (12)

Country Link
US (1) US20180256644A1 (enExample)
EP (1) EP3350206A1 (enExample)
JP (1) JP2018534245A (enExample)
KR (1) KR20180054713A (enExample)
CN (1) CN108513576A (enExample)
AU (1) AU2016323069A1 (enExample)
BR (1) BR112018004965A2 (enExample)
CA (1) CA2997217A1 (enExample)
EA (1) EA201890729A1 (enExample)
IL (1) IL258102A (enExample)
MX (1) MX2018003144A (enExample)
WO (1) WO2017048878A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045660B (zh) 2013-03-13 2023-09-01 伊麦吉纳博公司 与cd8的抗原结合构建体
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
MA43163A (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
AU2017345764A1 (en) * 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス, インコーポレイテッド Cd80細胞外ドメインポリペプチドによる治療方法
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) * 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
EP3735417A1 (en) * 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP7315703B2 (ja) * 2018-12-24 2023-07-26 ▲海▼▲東▼ 黄 組み換えヒト2Ig-B7-H3タンパク質コーディング遺伝子、組換えベクター及びそれを含む宿主細胞、並びに薬物組成物及びその応用
EP3908372A1 (en) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin-2
US12378299B2 (en) * 2019-04-26 2025-08-05 Xuanzhu Biopharmaceutical Co., Ltd. CD80 variant proteins and uses thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
CN113087806B (zh) * 2019-12-31 2022-09-06 华东师范大学 靶向多种肿瘤的新型car-t细胞及其制备和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
JP2004513878A (ja) * 2000-06-23 2004-05-13 マキシジェン, インコーポレイテッド 新規同時刺激分子
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
EP2726101B1 (en) * 2011-06-30 2018-08-08 Genzyme Corporation Inhibitors of t-cell activation
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
SG10201609447XA (en) * 2012-05-11 2017-01-27 Medimmune Llc Ctla-4 variants
GB201311475D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
EP3283508B1 (en) * 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities

Similar Documents

Publication Publication Date Title
JP2018534245A5 (enExample)
JP2020500010A5 (enExample)
TWI809130B (zh) 嵌合跨膜蛋白及其用途
JP2020511136A5 (enExample)
JP7433348B2 (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
JP2020114264A5 (enExample)
JP2019531328A5 (enExample)
RU2017133637A (ru) Иммуномодулирующие слитые белки и пути их применения
JP2017501702A5 (enExample)
JP2018504459A5 (enExample)
US20220389075A1 (en) Engineered t cell receptors and uses thereof
Stanietsky et al. Paired NK cell receptors controlling NK cytotoxicity
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
WO2019127215A1 (en) Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
NZ759969A (en) Tagged chimeric effector molecules and receptors thereof
KR20180054713A (ko) 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
JP2020515259A5 (enExample)
JP2017519502A5 (enExample)
JP2016506761A5 (enExample)
JP2021501587A (ja) Cd38指向性キメラ抗原受容体構築物
JP2017518071A5 (enExample)
JP7723420B2 (ja) B細胞標的化並列CAR(pCAR)治療的薬剤
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
JPWO2022178367A5 (enExample)